Zhaoke Ophthalmology Limited (HKEX: 06622) announced the signing of a definitive agreement to acquire global rights to NVK002 (atropine sulfate eye drops), a proprietary low-concentration atropine formulation for slowing myopia progression in children. Under the deal, Zhaoke obtains worldwide ownership of all intellectual property, regulatory filings, clinical data, trademarks, and manufacturing capabilities associated with NVK002. The agreement supersedes the original 2020 regional license under which Nevakar Pharmaceuticals, a Bridgewater, New Jersey-based private specialty pharma company, had granted Zhaoke rights covering Greater China, South Korea, and 11 Southeast Asian markets.
As part of the transaction, Zhaoke granted Nevakar a perpetual, royalty-free, exclusive license to develop and commercialize NVK002 in the United States. Financial terms of the acquisition were not disclosed.
Why it matters
The structural inversion here is unusual: a regional licensee acquiring full global IP ownership from the originator, then granting back the most commercially significant single-country market on a royalty-free basis, is rare in pharmaceutical deal-making. It signals that Zhaoke had accumulated sufficient operational control — through Phase III clinical execution, manufacturing buildout, and multi-market regulatory filings — to negotiate from a position of strength, effectively absorbing the asset from its originator.
The timing is relevant. Zhaoke's NVK002 registration application for Australia's Therapeutic Goods Administration was accepted for evaluation in June 2026, based on positive Phase III data. With regulatory momentum building across multiple markets simultaneously, the June 2026 deal consolidates rights at a point of maximum near-term optionality — before commercial revenues begin to materialize and asset valuation increases further.
Deal context
The 2026 transaction replaces the original October 2020 license agreement between Nevakar and Zhaoke, which was a conventional regional in-license. The financial terms of that original deal were not publicly disclosed. Zhaoke has also executed sub-licenses for NVK002 to AFT Pharmaceuticals (Australia/New Zealand), Senju Pharmaceutical (Japan), and Ferron Par (Middle East), demonstrating that it was already functioning as a de facto global rights manager before the formal acquisition.